Jean‐Michel Molina

38.2k total citations · 6 hit papers
547 papers, 18.7k citations indexed

About

Jean‐Michel Molina is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jean‐Michel Molina has authored 547 papers receiving a total of 18.7k indexed citations (citations by other indexed papers that have themselves been cited), including 363 papers in Infectious Diseases, 233 papers in Virology and 217 papers in Epidemiology. Recurrent topics in Jean‐Michel Molina's work include HIV/AIDS drug development and treatment (231 papers), HIV Research and Treatment (231 papers) and HIV/AIDS Research and Interventions (192 papers). Jean‐Michel Molina is often cited by papers focused on HIV/AIDS drug development and treatment (231 papers), HIV Research and Treatment (231 papers) and HIV/AIDS Research and Interventions (192 papers). Jean‐Michel Molina collaborates with scholars based in France, United States and United Kingdom. Jean‐Michel Molina's co-authors include Francis Derouin, David T. Scadden, Jerome E. Groopman, Christine Katlama, Constance Delaugerre, Claudine Sarfati, Geneviève Chêne, Raphaël Porcher, Matthieu Lafaurie and Michael S. Saag and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jean‐Michel Molina

524 papers receiving 18.1k citations

Hit Papers

HLA-B*5701 Screening for Hypersensitivity to Abacavir 2008 2026 2014 2020 2008 2018 2022 2022 2023 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HLA-B*5701 Screening for Hypersensitivity to Abacavir
    2008 1.2k citations Jean‐Michel Molina et al. profile →
  2. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
    2018 401 citations Jean‐Michel Molina et al. profile →
  3. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
    2022 320 citations Jean‐Michel Molina et al. profile →
  4. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
    2022 164 citations Jean‐Michel Molina et al. profile →
  5. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023
    2023 75 citations Juan Ambrosioni, Laura Levi et al. HIV Medicine profile →
  6. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design
    2024 69 citations Jean‐Michel Molina, Béatrice Berçot et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Michel Molina France 70 11.4k 7.2k 5.9k 2.6k 1.5k 547 18.7k
Brian Gazzard United Kingdom 77 12.2k 1.1× 8.9k 1.2× 7.0k 1.2× 3.3k 1.3× 2.4k 1.6× 494 21.8k
Rainer Weber Switzerland 78 13.2k 1.2× 7.9k 1.1× 6.6k 1.1× 7.3k 2.8× 1.4k 1.0× 407 23.7k
Adriano Lazzarin Italy 70 12.2k 1.1× 10.9k 1.5× 6.2k 1.1× 3.4k 1.3× 2.8k 1.9× 616 20.6k
Henry Masur United States 88 10.4k 0.9× 6.1k 0.8× 17.4k 3.0× 2.6k 1.0× 5.1k 3.4× 375 33.5k
William G. Powderly United States 67 13.0k 1.1× 3.9k 0.5× 10.5k 1.8× 3.5k 1.3× 670 0.5× 301 19.4k
Stephen A. Spector United States 67 7.6k 0.7× 6.5k 0.9× 7.9k 1.4× 1.7k 0.6× 2.5k 1.7× 319 16.2k
Santiago Moreno Spain 58 7.2k 0.6× 3.4k 0.5× 5.5k 0.9× 2.1k 0.8× 816 0.5× 552 12.8k
Diane V. Havlir United States 68 15.6k 1.4× 11.7k 1.6× 6.8k 1.2× 3.0k 1.1× 3.0k 2.0× 390 22.3k
Andrea Antinori Italy 64 9.9k 0.9× 7.4k 1.0× 4.1k 0.7× 3.0k 1.1× 648 0.4× 561 15.4k
Bernard Hirschel Switzerland 71 11.4k 1.0× 8.8k 1.2× 5.4k 0.9× 3.6k 1.4× 1.1k 0.8× 337 17.5k

Countries citing papers authored by Jean‐Michel Molina

Since Specialization
Citations

This map shows the geographic impact of Jean‐Michel Molina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Michel Molina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Michel Molina more than expected).

Fields of papers citing papers by Jean‐Michel Molina

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Michel Molina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Michel Molina. The network helps show where Jean‐Michel Molina may publish in the future.

Co-authorship network of co-authors of Jean‐Michel Molina

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Michel Molina. A scholar is included among the top collaborators of Jean‐Michel Molina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Michel Molina. Jean‐Michel Molina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Orkin, Chloe, Andrea Antinori, Jürgen K. Rockstroh, et al.. (2024). Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy. AIDS. 38(7). 983–991. 5 indexed citations
3.
Hazra, Aniruddha, Connie Celum, Anne F. Luetkemeyer, Jean‐Michel Molina, & Jeffrey D. Klausner. (2024). Reply to Keyon. Clinical Infectious Diseases. 80(1). 229–230. 2 indexed citations
4.
Caméléna, François, Élise Brottet, Cécile Bébéar, et al.. (2024). Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023. Emerging infectious diseases. 30(9). 1903–1906. 5 indexed citations
5.
6.
Ambrosioni, Juan, Laura Levi, Jasmini Alagaratnam, et al.. (2023). Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Medicine. 24(11). 1126–1136. 75 indexed citations breakdown →
7.
Maggiolo, Franco, Giuliano Rizzardini, Jean‐Michel Molina, et al.. (2022). Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age. HIV Medicine. 24(1). 27–36. 27 indexed citations
8.
Robineau, Olivier, I. Alcaraz, Victoria Manda, et al.. (2021). Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. The Lancet Infectious Diseases. 21(10). 1441–1447. 43 indexed citations
9.
Onodi, Fanny, Lucie Bonnet‐Madin, Laurent Meertens, et al.. (2021). SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4. The Journal of Experimental Medicine. 218(4). 80 indexed citations
10.
Molina, Jean‐Michel, Yazdan Yazdanpanah, Christopher Bettacchi, et al.. (2020). Islatravir in combination with doravirine maintains HIV-1 viral suppression through 96 weeks. Journal of the International AIDS Society. 8 indexed citations
11.
Noret, Marion, Claire Pintado, Martin Siguier, et al.. (2018). Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. AIDS. 32(15). 2161–2169. 38 indexed citations
12.
Moore, Cecilia L., Eduardo Gotuzzo, Adeeba Kamarulzaman, et al.. (2016). Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study. AIDS Research and Human Retroviruses. 32(9). 841–850. 12 indexed citations
13.
Amin, Janaki, Mark Boyd, Nagalingeswaran Kumarasamy, et al.. (2015). Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. PLoS ONE. 10(2). e0118228–e0118228. 31 indexed citations
14.
Barrail‐Tran, Aurélie, Corine Vincent, Valérie Furlan, et al.. (2015). Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir. Antimicrobial Agents and Chemotherapy. 59(12). 7903–7905. 2 indexed citations
15.
Raffi, François, Abdel G. Babiker, Laura Richert, et al.. (2014). Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.. The Lancet Neurology. 384(9958). 1 indexed citations
16.
Molina, Jean‐Michel. (2008). CASTLE: Atazanavir-Ritonavir vs Lopinavir-Ritonavir in Antiretroviral-Naïve HIV-1 Infected Patients: 96 Week Efficacy & Safety. 46th Annual Meeting. 2 indexed citations
17.
Chêne, Geneviève, Bahia Amellal, G. Pédrono, et al.. (2007). Changes in the Peripheral Blood mtDNA Levels in Naive Patients Treated by Different Nucleoside Reverse Transcriptase Inhibitor Combinations and Their Association with Subsequent Lipodystrophy. AIDS Research and Human Retroviruses. 23(1). 54–61. 8 indexed citations
18.
Molina, Jean‐Michel, Thomas Podsadecki, Margaret Johnson, et al.. (2007). A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 Weeks. AIDS Research and Human Retroviruses. 23(12). 1505–1514. 57 indexed citations
19.
Fournier, Sylvie, Claire Rabian, Corinne Alberti, et al.. (2001). Immune Recovery under Highly Active Antiretroviral Therapy Is Associated with Restoration of Lymphocyte Proliferation and Interferon‐γ Production in the Presence ofToxoplasma gondiiAntigens. The Journal of Infectious Diseases. 183(11). 1586–1591. 24 indexed citations
20.
Molina, Jean‐Michel, et al.. (1987). Monoclonal antibody pattern of legionella pneumophila serogroup 1 associated with virulence in guinea pigs. 87. 71. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian Gazzard Breakdown of academic impact, for papers by Rainer Weber Breakdown of academic impact, for papers by Adriano Lazzarin Breakdown of academic impact, for papers by Henry Masur Breakdown of academic impact, for papers by William G. Powderly Breakdown of academic impact, for papers by Stephen A. Spector Breakdown of academic impact, for papers by Santiago Moreno Breakdown of academic impact, for papers by Diane V. Havlir Breakdown of academic impact, for papers by Andrea Antinori Breakdown of academic impact, for papers by Bernard Hirschel
Rankless by CCL
2026